Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix, SAIC, Australian Genome Research Facility, NimbleGen, Metabolon, US Army, UC Davis, Lion Bioscience


CombiMatrix, SAIC Collaborate on Biodefense Applications

CombiMatrix and Science Applications International announced a collaboration to develop microarray technology for identification of biothreat organisms.

The companies will apply some of the US Department of Defense funding they each have in hand for the collaboration, CombiMatrix said in a statement. Further financial details were not disclosed.

CombiMatrix, the life-sciences division of Newport Beach, Calif.-based Acacia Research, will supply its microarray platform to the collaboration while San Diego-based SAIC, an information technology supplier, will apply its suite of genomic assays and data mining tools.

Australian Genome Research Facility to Use NimbleGen Microarray Technology

The Australian Genome Research Facility will use microarray technology from NimbleGen Systems, the Madison, Wis.-based company said last week.

Joining NimbleGen’s “Custom Microarray Core Facility” program, AGRF will offer its researchers customized arrays produced with NimbleGen’s maskless array synthesizer technology.

AGRF, which has operations in Brisbane, Melbourne, and Adelaide, already has platforms from Affymetrix, Sequenom, and Applied Biosystems in place.

Metabolon raises $9 million in Series A Financing

Metabolon has raised $9 million in a Series A round of financing, the Research Triangle Park, NC-based firm announced last week.

Metabolon is developing a metabolomics platform for the discovery and development of drugs and early diagnosis of disease states. The firm was founded in 2001 and is headed by John Ryals, the former CEO of Paradigm Genetics.

Metabolon raised $4 million in a first round of venture capital funding in 2003.

US Army Purchases HTS Flexchip System

The US Army Medical Research Institute of Infectious Diseases has purchased HTS Biosystems’ Flexchip Kinetic Analysis System and related Affinity Chips, HTS said last week.

USAMRIID will use the array platform in its research into responding to bioterrorism threats, according to HTS. Terms of the agreement were not disclosed.

The Flexchip system is a surface plasmon resonance array platform, which was previously sold by Applied Biosystems as the 8500 Affinity Chip Analyzer. HTS took over marketing of the platform last week, after ABI decided it didn’t fit with its business strategy going forward.

UC Davis Opens Genome Facility

The University of California, Davis, has opened its new Genome and Biomedical Sciences Facility, the University announced last week.

The $95 million, 225,000-square-foot building will house the UC Davis Genome Center, the Department of Biomedical Engineering, and scientists from the UC Davis School of Medicine involved in genomics, bioinformatics, biomedical engineering, pharmacology and toxicology, and other research areas.

The Genome Center will house 17 faculty members and provide facilities for genomics, proteomics, and related research areas. The Department of Biomedical Engineering includes the Center for Molecular and Genomic Imaging.

Lion Co-CEOs, Supervisory Board Resign

Daniel Keesman, co-CEO and chief operating officer, and Martin Hollenhorst, co-CEO and chief financial officer, as well as all three members of the supervisory board of Heidelberg, Germany-based Lion Bioscience have resigned, the company said last week.

Thure Etzold, managing director for Lion Bioscience UK, will be responsible for product development and services, replacing Keesman; and Joseph Donahue, chief business officer for Lion Bioscience in North America, will assume responsibility for finance and administration.

The executives and supervisory board members Jurgen Dormann, Klaus Pohle, and Richard Roy resigned after Wednesday’s supervisory board meeting. A local German trade court will work with Lion’s majority shareholders to appoint a new supervisory board that will serve until a new board can be elected at the company’s annual general meeting.

Shareholders, including former CEO Friedrich von Bohlen, a major shareholder of the company, can be considered for those positions, which serve a corporate governance function. Von Bohlen resigned from Lion at the end of 2003.

Meanwhile, Lion is considering de-listing from the Nasdaq stock exchange.


The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.